Overview
Discounted cash flow
Income / accounting-based
Multiples & assets
Scenario
Toolbox
Weighted blend
$327.43
-41.90% vs spot
Sell
Spot price
$563.53
Mkt cap $44.45B
subtle cardAnalyst PT consensus
$773.13
+37.19% vs spot
subtle cardMethods covered
15 / 16
14 in blend
subtle cardFootball field
IDXX · fair-value range by method
Method comparison
IDXX · fair value by valuation framework
| Method | Category | Fair value | Range | vs spot | Weight | Driver | Conf. |
|---|---|---|---|---|---|---|---|
| DCF · FCFF | dcf | $551.05 | $394.08 – $809.29 | -2.21% | 23.7% | WACC 8.0%, g₀=19.0%, gₗ=3.4% | high |
| DCF · FCFE | dcf | $299.52 | $235.60 – $387.83 | -46.85% | 17.8% | kₑ 11.5%, g₀=19.0%, gₗ=3.4% | high |
| Residual income | income | $56.91 | $50.08 – $63.74 | -89.90% | 11.8% | BV 20.02, ROE 66.0% → kₑ | high |
| EVA / MVA | income | $462.68 | $407.16 – $518.20 | -17.90% | 8.3% | IC 2.5B, WACC 8.0% | high |
| P/E · sector | multiple | $287.76 | $253.23 – $322.29 | -48.94% | 14.2% | EPS 13.08 × peer P/E 22.0 | med |
| P/S · sector | multiple | $214.70 | $182.50 – $246.91 | -61.90% | 3.6% | Rev/sh 53.68 × peer P/S 4.00 | med |
| EV / EBITDA | multiple | $263.62 | $231.98 – $295.25 | -53.22% | 11.8% | EBITDA × peer 15.0× − ND 0.9B | high |
| EV / EBIT | multiple | $294.13 | $250.01 – $338.25 | -47.81% | 2.4% | EBIT × peer 18.0× − ND | med |
| EV / Sales | multiple | $171.31 | $145.61 – $197.01 | -69.60% | 2.4% | Sales × peer 3.40× − ND | med |
| PEG-anchored | multiple | $157.81 | $134.14 – $181.48 | -72.00% | 1.2% | PEG=1, fwd EPS g 12.1% | med |
| Earnings power | intrinsic | $158.21 | $139.23 – $177.20 | -71.93% | 0.6% | NOPAT / WACC, no growth | med |
| Graham revised | intrinsic | $600.68 | $510.58 – $690.78 | +6.59% | 0.6% | EPS×(8.5+2g)·4.4/Y | low |
| Lynch P/E=g | intrinsic | $248.85 | $211.52 – $286.17 | -55.84% | 0.6% | PE = g (19.0) | low |
| Book NAV | asset | $20.02 | $19.02 – $21.02 | -96.45% | 1.2% | (Assets − Liabilities) / Shares | high |
| Liquidation | asset | $8.16 | $6.94 – $9.38 | -98.55% | — | Cash 100% + non-cash 70% − Liab. | low |
| Reverse DCF | reverse | — | — | — | — | Implied g 19.2% · Aggressive — well above sector trend | high |
Cost-of-capital build-up
CAPM cost of equity, after-tax cost of debt, WACC. Risk-free as of 2026-05-12.
| Risk-free rate (US 10y Treasury)rf | 4.46% |
| Equity beta (1.57)β | × 1.57 |
| Equity risk premiumERP | 4.46% |
| Cost of equity (CAPM)kₑ | 11.48% |
| Pre-tax cost of debtkd | 3.55% |
| Effective tax ratet | 20.0% |
| After-tax cost of debt | 2.84% |
| Equity weight$1.6B | 59.8% |
| Debt weight$1.1B | 40.2% |
| WACC | 8.01% |
Growth assumptions
Blended forward growth used as DCF default; terminal pegged to long-run nominal GDP.
| Analyst forward revenue growthFMP | 9.43% |
| Analyst forward EPS growthFMP | 12.06% |
| Historical 5y revenue CAGRFY | 7.56% |
| Historical 5y EPS CAGRFY | 11.05% |
| Sustainable g (ROE × retention)Δ | 65.99% |
| Blended near-term growth (g₀) | 19.02% |
| Terminal growth (gₗ) | 3.37% |
Sources
- FMP /analyst-estimates— 8 rows(as of 2023-12-31)
- Treasury rates · 10y— 4.46% rf(as of 2026-05-12)
- market_risk_premium · DB— 4.46% ERP(as of 2026-05-13)
- Sector multiple defaults— Healthcare (live sector PE unavailable)
- FMP /price-target-consensus— mean $773.13
This page is generated by a quantitative valuation engine for research purposes only and does not constitute investment advice. Methodology follows standard CFA / Damodaran frameworks; assumptions are driven by analyst consensus from Financial Modeling Prep and reported financial statements.